Lantheus Holdings, Inc. (NASDAQ:LNTH) Stake Lifted by Sanctuary Advisors LLC

Sanctuary Advisors LLC increased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 58.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,042 shares of the medical equipment provider’s stock after purchasing an additional 6,656 shares during the period. Sanctuary Advisors LLC’s holdings in Lantheus were worth $1,674,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in LNTH. State of New Jersey Common Pension Fund D boosted its position in shares of Lantheus by 0.4% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider’s stock valued at $2,364,000 after purchasing an additional 115 shares in the last quarter. Rhumbline Advisers lifted its stake in Lantheus by 1.5% during the fourth quarter. Rhumbline Advisers now owns 212,673 shares of the medical equipment provider’s stock valued at $19,026,000 after purchasing an additional 3,136 shares during the last quarter. Van ECK Associates Corp boosted its holdings in Lantheus by 31.7% during the fourth quarter. Van ECK Associates Corp now owns 76,996 shares of the medical equipment provider’s stock worth $6,888,000 after buying an additional 18,524 shares in the last quarter. MeadowBrook Investment Advisors LLC grew its position in Lantheus by 40.1% in the fourth quarter. MeadowBrook Investment Advisors LLC now owns 2,305 shares of the medical equipment provider’s stock worth $206,000 after buying an additional 660 shares during the last quarter. Finally, JSF Financial LLC bought a new position in shares of Lantheus in the fourth quarter valued at $894,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on LNTH shares. JMP Securities reissued a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. The Goldman Sachs Group assumed coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target on the stock. Finally, Truist Financial reaffirmed a “buy” rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $131.86.

Insider Activity

In other news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.50% of the stock is owned by corporate insiders.

Lantheus Trading Up 0.9 %

Shares of Lantheus stock opened at $78.95 on Tuesday. Lantheus Holdings, Inc. has a 1 year low of $56.44 and a 1 year high of $126.89. The company has a market cap of $5.49 billion, a P/E ratio of 13.14 and a beta of 0.44. The stock has a 50-day moving average price of $90.02 and a 200 day moving average price of $96.93.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.